{"id":70777,"date":"2026-07-28T18:07:57","date_gmt":"2026-07-28T10:07:57","guid":{"rendered":"https:\/\/flcube.com\/?p=70777"},"modified":"2026-07-28T18:07:58","modified_gmt":"2026-07-28T10:07:58","slug":"astrazeneca-reports-solid-q2-2026-results-with-5-revenue-growth-despite-farxiga-exclusivity-loss-and-china-vbp-headwinds","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70777","title":{"rendered":"AstraZeneca Reports Solid Q2 2026 Results with 5% Revenue Growth Despite Farxiga Exclusivity Loss and China VBP Headwinds"},"content":{"rendered":"\n

AstraZeneca plc<\/strong> (NYSE: AZN<\/a>) announced financial results for the second quarter and first half of 2026, delivering USD 15.384 billion in Q2 total revenue<\/strong>, representing 5% year-on-year growth at constant exchange rates (CER)<\/strong>. The company reported USD 3.164 billion in operating profit<\/strong> and USD 5.158 billion in Core operating profit<\/strong>, up 10% year-on-year<\/strong>.<\/p>\n\n\n\n

Financial Highlights \u2013 H1 2026<\/h2>\n\n\n\n
Metric<\/th>H1 2026 Result<\/th>YoY Change (CER)<\/th><\/tr><\/thead>
Total Revenue<\/strong><\/td>USD 30.672 billion<\/td>+6%<\/td><\/tr>
Core Operating Profit<\/strong><\/td>Not disclosed<\/td>Not disclosed<\/td><\/tr>
Full-Year 2026 Guidance<\/strong><\/td>Mid-to-high single-digit % growth<\/td>On track<\/td><\/tr>
2030 Revenue Target<\/strong><\/td>USD 80 billion<\/td>Progress maintained<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Regional Performance \u2013 H1 2026<\/h2>\n\n\n\n
Region<\/th>Revenue<\/th>YoY Change (CER)<\/th><\/tr><\/thead>
United States<\/strong><\/td>USD 12.89 billion<\/td>+8%<\/td><\/tr>
Emerging Markets (ex-China)<\/strong><\/td>USD 4.809 billion<\/td>+10%<\/td><\/tr>
China<\/strong><\/td>USD 3.51 billion<\/td>-5%<\/td><\/tr>
Europe<\/strong><\/td>USD 6.822 billion<\/td>+8%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Therapy Area Performance \u2013 H1 2026<\/h2>\n\n\n\n
Therapy Area<\/th>Revenue<\/th>YoY Change (CER)<\/th>Key Drivers<\/th><\/tr><\/thead>
Oncology<\/strong><\/td>USD 14.123 billion<\/td>+15%<\/td>Tagrisso (osimertinib), Imfinzi (durvalumab) + Imjudo (tremelimumab)<\/td><\/tr>
Respiratory & Immunology (R&I)<\/strong><\/td>USD 4.75 billion<\/td>+9%<\/td>Not specified<\/td><\/tr>
Rare Disease<\/strong><\/td>USD 4.911 billion<\/td>+11%<\/td>Not specified<\/td><\/tr>
Cardiovascular, Renal and Metabolism (CVRM)<\/strong><\/td>USD 6.013 billion<\/td>-12%<\/td>Farxiga exclusivity loss in US, VBP in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Oncology Product Highlights<\/h3>\n\n\n\n